 Leap Therapeutics, Inc. NASDAQ:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of 2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of 1.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the 0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Leap from this offering are expected to be approximately 45 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Leap. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. In addition, Leap has granted the underwriters a 30-day option to purchase up to an aggregate of an additional 3,375,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The offering is expected to close on or about June 22, 2020, subject to satisfaction of customary closing conditions. 